New Healthcare research report from Business Monitor International is now available from Fast Market Research
Boston, MA -- (SBWIRE) -- 02/25/2013 -- BMI View: We expect that Jordan will continue to provide modest opportunities to research-based pharmaceutical manufacturers. In line with the authorities' efforts to expand healthcare insurance coverage, we envisage measures aiming to promote the use of cheaper generic medicines, in tandem with price-reduction strategies. Nevertheless, the expansion of government provision and the higher uptake of generic medicines will conspire to keep longer term growth steady, boosted by upward volume changes, with the patented drug market to continue to be supported by rising numbers of medical tourists.
View Full Report Details and Table of Contents
Headline Expenditure Projections
- Pharmaceuticals: JOD463mn (US$653mn) in 2011 to JOD501mn (US$707mn) in 2012; +8.1% in local currency terms and +8.1% in US dollar terms. Forecast unchanged from Q412.
- Healthcare: JOD1.73bn (US$2.45bn) in 2011 to JOD1.87bn (US$2.65bn) in 2012; +8.0% in local currency terms and +8.1% in US dollar terms. Forecast unchanged from Q412.
- Medical devices: JOD112mn (US$158mn) in 2011 to JOD121mn (US$171mn) in 2012; +8.3% in local currency terms and +8.4% in US dollar terms. Forecast unchanged from Q412.
Risk/Reward Rating: Jordan's composite Pharmaceutical Risk/Reward Ratings score for Q113 remains unchanged in relation to the previous quarter. At 49.9 out of the maximum 100, Jordan is again ranked 10th, out of the 30 markets surveyed in the Middle East and Africa region. Jordan's rewards and risk scores remain evenly balanced, with both components standing firmly above the regional averages.
Key Trends And Developments
- In July 2012, Hayel Obeidat, director general of the Jordanian Food and Drug Administration (FDA), said that the prices of 275 locally and internationally produced drugs had been reduced. The medicines affected by the changes include painkillers and treatments for chronic diseases and cancer. Any company or drugstore found guilty of not reducing drug prices in line with this policy will be penalised, Obeidat added. Fines totalling over JOD1mn (US$1.4mn) have already been collected from firms that rejected the immediate price reduction. The JFDA is now reviewing the reduction of prices for an additional 25 drugs.
- The number of foreign patients visiting Jordan for medical treatment increased by 7% year-onyear (y-o-y) in H112. Although medical tourism in Jordan has emerged as the most robust healthcare sector in the entire Middle East, Private Hospitals Association (PHA) President Fawzi Hammouri was quoted by Jordan Times as saying that the sector still needs to overcome certain challenges to achieve further growth in terms of patient numbers and revenues. He identified Jordanian visa regulations and continuing brain drain to be the major barriers for medical tourism to attain its maximum potential.
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Healthcare research reports at Fast Market Research
You may also be interested in these related reports:
- Nigeria Pharmaceuticals & Healthcare Report Q1 2013
- Sweden Pharmaceuticals & Healthcare Report Q1 2013
- Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2011
- Slovenia Pharmaceuticals & Healthcare Report Q1 2013
- Estonia Pharmaceuticals & Healthcare Report Q1 2013
- Kenya Pharmaceuticals & Healthcare Report Q1 2013
- Netherlands Pharmaceuticals & Healthcare Report Q1 2013
- South Korea Pharmaceuticals & Healthcare Report Q1 2013
- Mexico Pharmaceuticals & Healthcare Report Q1 2013
- Chile Pharmaceuticals & Healthcare Report Q1 2013